


## PI-828

<b>Cat. No.:</b>	HY-108606		
<b>CAS No.:</b>	942289-87-4		
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>18</sub> N <sub>2</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	322.36		
<b>Target:</b>	PI3K; Casein Kinase		
<b>Pathway:</b>	PI3K/Akt/mTOR; Cell Cycle/DNA Damage; Stem Cell/Wnt		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	PI-828 is a dual PI3K and casein kinase 2 (CK2) inhibitor with IC <sub>50</sub> s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2 α2 in lipid kinase assay, respectively <sup>[1]</sup> .																		
<b>IC<sub>50</sub> &amp; Target</b>	p110α 173 nM (IC <sub>50</sub> )	CK2 149 nM (IC <sub>50</sub> )	CK2α2 1.127 μM (IC <sub>50</sub> )																
<b>In Vitro</b>	<p>PI-828 (0.01-100 μM) exhibits cytotoxic effect on the 4T1 breast cancer cells and 4306 ovarian cancer cells<sup>[2]</sup>.</p> <p>PI-828 (0.78-3.12 μM; 48 hours) decreases caspase 3 activation; higher concentrations of PI-828 (6.25-12.5 μM) alone causes apoptosis<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>4T1 breast cancer cells and 4306 ovarian cancer cells</td> </tr> <tr> <td>Concentration:</td> <td>0.01, 0.1, 1, 10 and 100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td></td> </tr> <tr> <td>Result:</td> <td>Exhibited cytotoxic effect.</td> </tr> </table> <p>Apoptosis Analysis<sup>[3]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human embryonic carcinoma NCCIT cells</td> </tr> <tr> <td>Concentration:</td> <td>0.78, 1.56, 3.12, 6.25, 12.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Concentrations of ranging from 0.78 to 3.12 μM decreased caspase 3 activation; higher concentrations caused apoptosis.</td> </tr> </table>			Cell Line:	4T1 breast cancer cells and 4306 ovarian cancer cells	Concentration:	0.01, 0.1, 1, 10 and 100 μM	Incubation Time:		Result:	Exhibited cytotoxic effect.	Cell Line:	Human embryonic carcinoma NCCIT cells	Concentration:	0.78, 1.56, 3.12, 6.25, 12.5 μM	Incubation Time:	48 hours	Result:	Concentrations of ranging from 0.78 to 3.12 μM decreased caspase 3 activation; higher concentrations caused apoptosis.
Cell Line:	4T1 breast cancer cells and 4306 ovarian cancer cells																		
Concentration:	0.01, 0.1, 1, 10 and 100 μM																		
Incubation Time:																			
Result:	Exhibited cytotoxic effect.																		
Cell Line:	Human embryonic carcinoma NCCIT cells																		
Concentration:	0.78, 1.56, 3.12, 6.25, 12.5 μM																		
Incubation Time:	48 hours																		
Result:	Concentrations of ranging from 0.78 to 3.12 μM decreased caspase 3 activation; higher concentrations caused apoptosis.																		

### REFERENCES

---

[1]. Gharbi SI, et al. Exploring the specificity of the PI3K family inhibitor LY294002. *Biochem J.* 2007 May 15;404(1):15-21.

[2]. Zellefrow CD, et al. Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay. *Radiat Res.* 2012 Sep;178(3):150-9.

[3]. Kulkarni AA, et al. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. *Cancer Res.* 2013 Dec 1;73(23):6987-97.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA